NO-platform
NO platform allows you to synthesize original hybrid molecules consisting of pharmaceutically active compounds (API), prostaglandins (PG) and nitric oxide donors (NO-donors)
Main News
* Gurus successfully completed preclinical trials of asthma treatment drug * Magazine Kommersant published an article about promising multifunctional drug candidates of Gurus BioPharm * Gurus raises $0.7M for preclinical trials of a drug for asthma

Investments in biomedical innovations

Gurus BioPharm LLC (“Gurus”) is a research and investment company developing innovative drugs. We finance and develop groundbreaking Russian biopharmaceutical innovations from the early stages to commercialization at the global market. We provide an opportunity for accredited private investors to co-invest with us in cutting-edge innovations that can change current standards of healthcare in the world.

Projects for investment:

Innovative drugs

Innovative drugs
Respiratory system
Asthma treatment
Stage:
Innovative drugs
Genito-urinary system
Erectile dysfunction treatment (ED)
Stage:
Innovative drugs
Cardiovascular system
Critical Limb Ischemia treatment (CLI)
Stage:
All projects...

Highly Effective cosmetics

Highly Effective cosmetics
Anti-aging line
Anti-aging skin recovery
Stage:
Highly Effective cosmetics
Hair growth stimulation
Hair growth stimulator
Stage:
Highly Effective cosmetics
After cosmetic surgery
Skin recovery after cosmetic surgery
Stage:
All projects...

Synergy of investment and research capabilities

Unlike traditional life sciences funds, Gurus conducts scientific research of original molecules. Therefore, we can enter the projects before the traditional venture funds, at the stage of scientific research. Projects with some incompleteness in technology development do not confuse us, if they have strong innovative potential. Gurus has expertise and technological capabilities to eliminate the shortcomings of the project and to unlock its potential.

Our technologies in drug development

Gurus has strong research competencies and platform technologies in drug development. Noxi Lab is a technological unit of Gurus which develops a research platform for generating innovative drugs, based on nitric oxide donors and pharmaceutical substance hybridization technology which uses biologically active linkers.

Joint investments in drug development

Gurus offers to accredited private investors to co-invest together with us in biopharmaceutical innovations. Traditional life sciences venture funds and pharmaceutical companies do not collaborate with private investors. Investing in innovative drugs is assumed to be one of the most profitable and fastest growing industries in the world and can be an interesting alternative to investing in shares of mature public companies.

Our startups
Our project companies are Prostanit development, LLC, Noxi Lab, LLC